From February of 2022, subscribers will be able to view and filter individual regulatory alerts per region. If you want to get our alerts compilations, visit our alerts Round-up section.
29th November 2022
Brazil: The National Public Health Surveillance Agency (Anvisa) has authorised Canabidiol Ease Labs 100 mg/ml to be manufactured in Brazil in the form of a solution for oral use. The agency has already approved 23 cannabis-derived products.
18th November 2022
31st October 2022
25th October 2022
Brazil: The Federal Council of Medicine (CFM) has suspended a resolution restricting medical prescription of CBD after the Federal Public Prosecutor’s Office announced an investigation into its legality. The CFM left open a public consultation reviewing the resolution, which is due to end on 23rd December.
21st October 2022
20th October 2022
Brazil: Senator Mara Gabrilli, from the centre and independent Brazilian Social Democracy Party, has presented to the Senate a draft legislative decree to overturn a Federal Council of Medicine resolution restricting the prescription of CBD for medical use. Gabrilli said the resolution undermines the function of the National Public Health Surveillance Agency (Anvisa), which is the authority responsible for inspecting medicines.
18th October 2022
14th October 2022
10th October 2022
3rd October 2022
27th September 2022
Brazil: The National Public Health Surveillance Agency (Anvisa) has clarified that medical cannabis products cannot be sold through delivery services. Cannabis-derived products previously allowed by the agency must follow the rules for controlled drugs and can only be sold by pharmacies under prescription.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.